Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.
2.

A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.

Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, Xie Y, Chen C, Chan HL, Zhao M.

Clin Infect Dis. 2014 Dec 15;59(12):1714-23. doi: 10.1093/cid/ciu702.

3.

[HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].

Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.

Zhonghua Gan Zang Bing Za Zhi. 2013 Jul;21(7):502-5. doi: 10.3760/cma.j.issn.1007-3418.2013.07.007. Chinese.

PMID:
24074707
4.

[Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].

Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):335-9. doi: 10.3760/cma.j.issn.1007-3418.2013.05.006. Chinese.

PMID:
24025132
5.

[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].

Yue W, Yuan H, Mao XR, Deng YD, Chen L.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):184-8. Chinese.

PMID:
23967738
6.

[Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].

Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.

Zhonghua Gan Zang Bing Za Zhi. 2015 Nov;23(11):826-31. doi: 10.3760/cma.j.issn.1007-3418.2015.11.006. Chinese.

PMID:
26743242
7.

[Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].

Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.

Zhonghua Gan Zang Bing Za Zhi. 2012 Oct;20(10):737-41. doi: 10.3760/cma.j.issn.1007-3418.2012.10.006. Chinese.

PMID:
23207332
8.

The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.

Dogan UB, Golge N, Akin MS.

Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1312-6. doi: 10.1097/MEG.0b013e328362389a.

PMID:
23652913
9.

[A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].

Huang ZL, Zhao ZX, Deng H, Zhang YF, Lu CR, Gao ZL.

Zhonghua Gan Zang Bing Za Zhi. 2010 Jun;18(6):419-22. doi: 10.3760/cma.j.issn.1007-3418.2010.06.006. Chinese.

PMID:
20587310
10.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

11.

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).

Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL; ARES Study Group..

Hepatology. 2015 May;61(5):1512-22. doi: 10.1002/hep.27586.

PMID:
25348661
12.

Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.

Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P.

J Clin Virol. 2013 Dec;58(4):713-7. doi: 10.1016/j.jcv.2013.09.020.

PMID:
24183313
13.
14.

Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.

Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.

Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1165-9. doi: 10.1097/MEG.0b013e3283612e95.

PMID:
23571612
15.

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.

Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.

PLoS One. 2015 Apr 2;10(4):e0122259. doi: 10.1371/journal.pone.0122259.

16.

Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.

Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.

Antimicrob Agents Chemother. 2015 Jul;59(7):4121-8. doi: 10.1128/AAC.00249-15.

17.

[Factors influencing the curative effect in patients with HBeAgpositive chronic hepatitis B treated with peg-interferon α-2a].

Chen J, Zheng Q, Jiang J, Zheng J.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 Jul;37(7):714-9. doi: 10.3969/j.issn.1672-7347.2012.07.012. Chinese.

18.

Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.

Sonneveld MJ, Zoutendijk R, Hansen BE, Janssen HL.

Antivir Ther. 2012;17(8):1605-8. doi: 10.3851/IMP2319.

PMID:
22898565
19.

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.

Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2011;16(5):629-37. doi: 10.3851/IMP1841.

PMID:
21817184
20.

Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.

Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.

Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555.

PMID:
23486701
Items per page

Supplemental Content

Support Center